Late-Onset Systemic Lupus Erythematosus: Is It Really a Benign Disease?

Area of Science:

• Rheumatology
• Immunology
• Geriatrics

Background:

• Late-onset systemic lupus erythematosus (LO-SLE) is a distinct clinical subset of SLE with onset at age 50+.
• LO-SLE exhibits unique clinical and serological characteristics compared to earlier-onset disease.
• Immunosenescence is implicated in the pathophysiology of LO-SLE.

Purpose of the Study:

• To delineate the distinct features of LO-SLE.
• To discuss diagnostic complexities and management strategies for LO-SLE.

Main Methods:

• Review of clinical and serological profiles of LO-SLE patients.
• Application of 2019 ACR/EULAR classification criteria.
• Consideration of immunosenescence and comorbidities in diagnosis and management.

Main Results:

• LO-SLE often presents insidiously with less renal/mucocutaneous and more serositis, constitutional, and lung involvement.
• Serologically, LO-SLE patients may have less anti-dsDNA and more anti-SSA/Ro and anti-SSB/La antibodies.
• Diagnostic challenges arise due to reduced ANA specificity and comorbidities in older adults.

Conclusions:

• LO-SLE is a clinically and immunologically distinct entity requiring tailored management.
• Hydroxychloroquine is foundational, with cautious use of glucocorticoids and immunomodulators.
• Individualized treatment considering safety and comorbidities is crucial for effective LO-SLE management.